Company: ARTL
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001640334-25-002022
Chunk: 2

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
 common stock outstanding  787   538   698   536 

 4Table of Contents

ARTELO BIOSCIENCES, INC.

Consolidated Statements of Stockholders’ (Deficit) Equity

(Unaudited)

(In thousands)

    Additional    Accumulated Other      Common Stock  Paid-in  Accumulated  Comprehensive     Shares  Amount  Capital  Deficit  Income (loss)  Total                    Balance, December 31, 2024  567  $1  $53,194  $(50,136) $(202) $2,857                          Stock based compensation  -   -   192   -   -   192 Net loss for the period  -   -   -   (2,372)  -   (2,372)Other comprehensive loss  -   -   -   -   (25)  (25)Balance, March 31, 2025  567  $1  $53,386  $(52,508) $(227) $652                          Common stock issued for cash, net of issuance costs  137   -   1,081   -   -   1,081 Stock based compensation  -   -   150   -   -   150 Net loss for the period  -   -   -   (3,221)  -   (3,221)Other comprehensive loss  -   -   -   -   (68)  (68)Balance, June 30, 2025  704  $1  $54,617  $(55,729) $(295) $(1,406)                         Common stock issued for cash, net of issuance costs  750   1   3,310   -   -   3,311 Warrants exercised  101   -   132   -   -   132 Stock based compensation  -   -   432   -   -   432 Net loss for the period  -   -